title: [Spontaneous regression of multiple squamous cell carcinomas after discontinuation of adalimumab and methotrexate].
authors.affiliation: Service de dermatologie, hôpital Robert-Debré, CHU de Reims, avenue du Général-Koenig, 51092 Reims cedex, France. Electronic address: perrine.nicol@hotmail.fr.
authors.forename: P
authors.initials: P
authors.lastname: Nicol
authors.affiliation: Laboratoire Pol-Bouin, hôpital Robert-Debré, CHU de Reims, avenue du Général-Koenig, 51092 Reims cedex, France.
authors.forename: A
authors.initials: A
authors.lastname: Durlach
authors.affiliation: Service de dermatologie, hôpital Robert-Debré, CHU de Reims, avenue du Général-Koenig, 51092 Reims cedex, France.
authors.forename: P
authors.initials: P
authors.lastname: Bernard
authors.affiliation: Service de dermatologie, hôpital Robert-Debré, CHU de Reims, avenue du Général-Koenig, 51092 Reims cedex, France.
authors.forename: Z
authors.initials: Z
authors.lastname: Reguiaï
mesh_terms: D000068879:Adalimumab / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000627:therapeutic use; D015535:Arthritis, Psoriatic / Q000188:drug therapy; D002294:Carcinoma, Squamous Cell / Q000473:pathology*; D000068800:Etanercept / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008727:Methotrexate / Q000627:therapeutic use; D008875:Middle Aged; D009365:Neoplasm Regression, Spontaneous; D009378:Neoplasms, Multiple Primary / Q000473:pathology*; D011565:Psoriasis / Q000188:drug therapy; D012878:Skin Neoplasms / Q000473:pathology*; D028761:Withholding Treatment
chemical_list: D018501:Antirheumatic Agents; D000068879:Adalimumab; D000068800:Etanercept; D008727:Methotrexate